🔗 Share this article

Given that the US proceeds with sweeping revisions to its vaccination guidelines, one figure has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by casting doubt on Covid vaccinations in the global health crisis and has focused upon possible fatalities after COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders had intended to reveal radical revisions to the childhood immunization program in December, aligning the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of step with many the global community with insufficient data for public health gain. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A New Direction at the FDA

This interim role could signify a strengthened alliance between the drug and biologics branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood immunization guidelines in the US to become more like Denmark, a country with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – usually the purview of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been typical for former heads of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who headed the center have had.”

The drug center has an immense workload at the FDA, the former commissioner emphasized.

“Many people just focuses on the innovative therapies, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and each of these have to be looked after,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the position, which supervises in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” Woodcock said.

Official Statement and Controversial Policies

When asked about concerns about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “questions are based on incorrect assumptions”.

“Her resume aligns with the duties of her role,” the representative stated, noting the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a contentious one-day therapy clearance system that apparently troubled her former heads. “How are these medications being selected for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent oversight of most medications, aside from vaccines.”

Documented Past Work on Vaccines

With vaccines, Høeg has a clearer, if problematic, past, some experts said. She released a study using non-validated crowd-sourced reports to estimate the incidence of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are riskier than they are.

Among her “desired changes” for the new federal leadership featured revising rules for recently developed shots and halting “optional” immunizations, she stated following the vote on a audio program. At the agency, Høeg has according to sources proposed barring young men from getting COVID-19 vaccines.

“She’s an all-around true believer who commences with her conclusions and works backwards to fit the evidence in a highly misleading, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined fellow contrarians, {like|